Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this closing segment, Dr. Charles J. Ryan leads a discussion on how clinicians integrate multiple sources of evidence when making long term treatment decisions in metastatic castration sensitive prostate cancer (mCSPC). Dr. Murilo De Almeida Luz explains how physicians balance data from randomized clinical trials, insights from real world evidence, and individual patient goals such as maintaining independence, minimizing treatment burden, and preserving quality of life. The panel emphasizes that treatment decisions in mCSPC increasingly require a personalized approach that considers patient preferences, comorbidities, and long term tolerability of therapy. The discussion then shifts to remaining evidence gaps in the field, with panelists highlighting the need for additional research to better understand outcomes in older and more medically complex patients who may be underrepresented in clinical trials. The segment concludes with reflections from the panel on future directions in metastatic castration sensitive prostate cancer and the importance of continued research to support evidence informed clinical decision making.